Literature DB >> 29276179

CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia.

Esmaeil Allahmoradi1, Saeid Taghiloo, Mohsen Tehrani, Hadi Hossein-Nattaj, Ghasem Janbabaei, Ramin Shekarriz, Hossein Asgarian-Omran.   

Abstract

BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. This health problem is caused due to the accumulation of mature B-lymphocytes in the peripheral blood and bone marrow. In the course of cancer, CD4+ T cells become "exhausted" and characterized with poor effector functions and the expression of multiple inhibitory receptors.
OBJECTIVE: To investigate the frequency and functional properties of exhausted CD4+ T lymphocytes in patients with CLL.
METHODS: Peripheral blood mononuclear cells were obtained from 25 untreated CLL patients and 15 healthy volunteers. CLL patients were clinically classified according to the Rai staging system. The frequency of CD4+/Tim-3+/PD-1+ cells was obtained by flow cytometry. To evaluate cell proliferation and cytokine production, CD4+ T cells were isolated and stimulated with phytohemagglutinin and PMA/ionomycin. Concentrations of IL-2, IFN-γ, TNF-α, and IL-10 were measured in the culture supernatants of stimulated cells by the ELISA technique.
RESULTS: The percentage of CD4+/Tim-3+/PD-1+ cells was significantly higher in CLL patients than that of healthy controls. CD4+ T cells from CLL patients showed lower proliferative responses, a lower production of IL-2, IFN-γ, and TNF-α, and a higher production of IL-10, compared to healthy controls. CD4+ T cells from CLL patients in advanced clinical stages showed more exhaustion features than those of early stages.
CONCLUSION: Given that the exhaustion phase of T cells can be reversible, targeted blocking of immune inhibitory molecules could be a promising tool to restore the host immune responses against leukemic cells in CLL.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29276179     DOI: IJIv14i4A1

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  8 in total

Review 1.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

2.  Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.

Authors:  Anna Pawłowska; Dorota Suszczyk; Rafał Tarkowski; Roman Paduch; Jan Kotarski; Iwona Wertel
Journal:  Cancer Manag Res       Date:  2020-10-07       Impact factor: 3.989

Review 3.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

Review 4.  CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Authors:  Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2021-06-14       Impact factor: 12.531

5.  Expression of PD-1 on CD4+ Tumor-Infiltrating Lymphocytes in Tumor Microenvironment Associated with Pathological Characteristics of Breast Cancer.

Authors:  Yan-Jie Zhao; Jian Zhang; Feng Shi; Zhi-Ping Hu; Jiang-Ping Wu; Guang-Jiang Wu; Rui-Bin Wang; Quan Zhou; Hong Chang; Ying-Nan Li; Qing-Kun Song
Journal:  J Immunol Res       Date:  2018-07-04       Impact factor: 4.818

6.  Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL).

Authors:  Adam Suleman; Ruth Padmore; Carolyn Faught; Juthaporn Cowan
Journal:  IDCases       Date:  2019-05-31

7.  Shift in Epidemiology of Cryptococcal Infections in Ottawa with High Mortality in Non-HIV Immunocompromised Patients.

Authors:  Vishesh Patel; Marc Desjardins; Juthaporn Cowan
Journal:  J Fungi (Basel)       Date:  2019-11-10

8.  Expression Analysis of Fyn and Bat3 Signal Transduction Molecules in Patients with Chronic Lymphocytic Leukemia.

Authors:  Fereshteh Hosseini-Valiki; Saeid Taghiloo; Golvash Tavakolian; Omolbanin Amjadi; Mohsen Tehrani; Akbar Hedayatizadeh-Omran; Reza Alizadeh-Navaei; Ehsan Zaboli; Ramin Shekarriz; Hossein Asgarian-Omran
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.